518 related articles for article (PubMed ID: 25196265)
21. Simultaneous determination of MAO-A and -B activity following first time intake of an irreversible MAO-B inhibitor in patients with Parkinson's disease.
Müller T; Riederer P; Grünblatt E
J Neural Transm (Vienna); 2017 Jun; 124(6):745-748. PubMed ID: 28299453
[TBL] [Abstract][Full Text] [Related]
22. Efficacy, safety and tolerability of rasagiline as adjunctive therapy in elderly patients with Parkinson's disease.
Tolosa E; Stern MB
Eur J Neurol; 2012 Feb; 19(2):258-64. PubMed ID: 21819487
[TBL] [Abstract][Full Text] [Related]
23. Monoamine oxidase-B inhibitors in the treatment of Parkinson's disease: clinical-pharmacological aspects.
Riederer P; Müller T
J Neural Transm (Vienna); 2018 Nov; 125(11):1751-1757. PubMed ID: 29569037
[TBL] [Abstract][Full Text] [Related]
24. Rasagiline mesylate, a new MAO-B inhibitor for the treatment of Parkinson's disease: a double-blind study as adjunctive therapy to levodopa.
Rabey JM; Sagi I; Huberman M; Melamed E; Korczyn A; Giladi N; Inzelberg R; Djaldetti R; Klein C; Berecz G;
Clin Neuropharmacol; 2000; 23(6):324-30. PubMed ID: 11575866
[TBL] [Abstract][Full Text] [Related]
25. Rasagiline for the treatment of Parkinson's disease: an update.
Stocchi F; Fossati C; Torti M
Expert Opin Pharmacother; 2015; 16(14):2231-41. PubMed ID: 26364897
[TBL] [Abstract][Full Text] [Related]
26. Clinical pharmacology of rasagiline: a novel, second-generation propargylamine for the treatment of Parkinson disease.
Chen JJ; Swope DM
J Clin Pharmacol; 2005 Aug; 45(8):878-94. PubMed ID: 16027398
[TBL] [Abstract][Full Text] [Related]
27. Monoamine Oxidase B Inhibitors in Parkinson's Disease.
Dezsi L; Vecsei L
CNS Neurol Disord Drug Targets; 2017; 16(4):425-439. PubMed ID: 28124620
[TBL] [Abstract][Full Text] [Related]
28. The monoamine oxidase type B inhibitor rasagiline in the treatment of Parkinson disease: is tyramine a challenge?
Chen JJ; Wilkinson JR
J Clin Pharmacol; 2012 May; 52(5):620-8. PubMed ID: 21628600
[TBL] [Abstract][Full Text] [Related]
29. Medical management of levodopa-associated motor complications in patients with Parkinson's disease.
Jankovic J; Stacy M
CNS Drugs; 2007; 21(8):677-92. PubMed ID: 17630819
[TBL] [Abstract][Full Text] [Related]
30. Rasagiline meta-analysis: a spotlight on clinical safety and adverse events when treating Parkinson's disease.
Solís-García del Pozo J; Mínguez-Mínguez S; de Groot PW; Jordán J
Expert Opin Drug Saf; 2013 Jul; 12(4):479-86. PubMed ID: 23634791
[TBL] [Abstract][Full Text] [Related]
31. Pharmacological aspects of the neuroprotective effects of irreversible MAO-B inhibitors, selegiline and rasagiline, in Parkinson's disease.
Szökő É; Tábi T; Riederer P; Vécsei L; Magyar K
J Neural Transm (Vienna); 2018 Nov; 125(11):1735-1749. PubMed ID: 29417334
[TBL] [Abstract][Full Text] [Related]
32. Rasagiline: a guide to its use in Parkinson's disease.
Keating GM; Lyseng-Williamson KA; Hoy SM
CNS Drugs; 2012 Sep; 26(9):781-5. PubMed ID: 22834567
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of adjunctive rasagiline in Japanese Parkinson's disease patients with wearing-off phenomena: A phase 2/3, randomized, double-blind, placebo-controlled, multicenter study.
Hattori N; Takeda A; Takeda S; Nishimura A; Kato M; Mochizuki H; Nagai M; Takahashi R
Parkinsonism Relat Disord; 2018 Aug; 53():21-27. PubMed ID: 29748109
[TBL] [Abstract][Full Text] [Related]
34. Understanding Parkinson's disease: an update on current diagnostic and treatment strategies.
Pahwa R
J Am Med Dir Assoc; 2006 Sep; 7(7 Suppl 2):4-10. PubMed ID: 17948613
[TBL] [Abstract][Full Text] [Related]
35. Rasagiline adjunct therapy in patients with Parkinson's disease: post hoc analyses of the PRESTO and LARGO trials.
Elmer LW
Parkinsonism Relat Disord; 2013 Nov; 19(11):930-6. PubMed ID: 23849501
[TBL] [Abstract][Full Text] [Related]
36. Rasagiline: A second-generation monoamine oxidase type-B inhibitor for the treatment of Parkinson's disease.
Chen JJ; Ly AV
Am J Health Syst Pharm; 2006 May; 63(10):915-28. PubMed ID: 16675649
[TBL] [Abstract][Full Text] [Related]
37. Rasagiline: a novel anti-Parkinsonian monoamine oxidase-B inhibitor with neuroprotective activity.
Weinreb O; Amit T; Bar-Am O; Youdim MB
Prog Neurobiol; 2010 Nov; 92(3):330-44. PubMed ID: 20600573
[TBL] [Abstract][Full Text] [Related]
38. Comparative efficacy and safety of monoamine oxidase type B inhibitors plus channel blockers and monoamine oxidase type B inhibitors as adjuvant therapy to levodopa in the treatment of Parkinson's disease: a network meta-analysis of randomized controlled trials.
Yan R; Cai H; Cui Y; Su D; Cai G; Lin F; Feng T
Eur J Neurol; 2023 Apr; 30(4):1118-1134. PubMed ID: 36437702
[TBL] [Abstract][Full Text] [Related]
39. Rasagiline in Parkinson's disease.
Chahine LM; Stern MB
Int Rev Neurobiol; 2011; 100():151-68. PubMed ID: 21971007
[TBL] [Abstract][Full Text] [Related]
40. The role of rasagiline in the treatment of Parkinson's disease.
Leegwater-Kim J; Bortan E
Clin Interv Aging; 2010 May; 5():149-56. PubMed ID: 20517484
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]